Comprehensive Assessment of TOS-358: A Novel Covalent PI3Kα Inhibitor

I. Executive Summary

(This section will be drafted upon completion of the detailed analysis to provide a concise overview of TOS-358, including its mechanism, preclinical and early clinical findings, intellectual property standing, and overall therapeutic potential in the context of PIK3CA-mutated cancers.)

II. Introduction to TOS-358

Overview of TOS-358 as an Investigational Agent

TOS-358 is an investigational, orally bioavailable, small molecule therapeutic agent.[1] It functions as a covalent inhibitor specifically targeting the alpha isoform of the class I phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) catalytic subunit, commonly known as PIK3CA or PI3K p110alpha.[1] The development of TOS-358 is primarily focused on its potential as an antineoplastic agent for various solid tumors that are characterized by mutations or amplifications in the PIK3CA gene.[4] The prevalence of PIK3CA mutations across a wide array of common cancers, including breast, colorectal, and lung cancer, underscores the significant therapeutic potential of a highly effective and specific PI3Kα inhibitor.[1]

Developer: Totus Medicines and its Discovery Platform

TOS-358 is under development by Totus Medicines.[8] The company employs a proprietary drug discovery engine, the Accel™ Platform, which integrates covalent DNA-encoded libraries with advanced artificial intelligence and machine learning (AI/ML) methodologies.[7] This platform is designed to accelerate the identification and optimization of novel drug candidates. The development timeline for TOS-358 itself highlights the potential efficiency of this platform, with reports indicating its discovery within a four-month timeframe and the achievement of Investigational New Drug (IND) application approval approximately two years after the initial screening process.[7] Such rapid progression from discovery to clinical testing suggests a capacity for Totus Medicines to potentially bring new covalent inhibitors to clinical evaluation more swiftly than is typical with conventional drug discovery paradigms, which could confer a notable advantage in the competitive landscape of oncology drug development.

Therapeutic Target: The PI3Kα Pathway in Oncology

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a central signaling network that governs critical cellular processes, including growth, proliferation, survival, and metabolism. Dysregulation of this pathway is a hallmark of many human cancers.[1] The PIK3CA gene, which encodes the p110α catalytic subunit of PI3K, is one of the most frequently mutated oncogenes in human tumors, driving the progression of numerous solid malignancies.[1] Consequently, PI3Kα represents a highly rational and attractive target for anticancer drug development. However, the development of PI3K inhibitors has historically been challenged by issues of off-target toxicity and limited efficacy, often due to insufficient target engagement or the development of resistance.[7] This context underscores the medical need for novel PI3Kα inhibitors like TOS-358 that can offer improved specificity, more profound and sustained target inhibition, and a better therapeutic window.

Table 1: Overview of TOS-358

Feature	Description
Drug Name (Code)	TOS-358 4
Synonyms	PI3K-alpha inhibitor TOS-358, PI3Kα inhibitor TOS-358, TOS 358, TOS358 1
Developer	Totus Medicines 9
Drug Type	Small molecule 8
Target	PI3Kα (Phosphatidylinositol 3 kinase alpha / PIK3CA) 1
Mechanism Class	Covalent PI3Kα inhibitor 1
Route of Administration	Oral 1
Current Development Phase	Phase 1/1b clinical trial 8

III. Mechanism of Action and Scientific Rationale

Covalent Inhibition of PI3Kα (Wild-Type and Mutant Forms)

TOS-358 is distinguished by its mechanism as a covalent inhibitor of PI3Kα. It is designed to selectively target and form a covalent bond with both wild-type PIK3CA and its various mutated forms commonly found in cancers.[1] This covalent interaction is intended to achieve a profound and durable inactivation of PI3Kα enzyme activity.[7] Unlike non-covalent inhibitors, which bind reversibly and whose target occupancy can fluctuate with pharmacokinetic profiles, covalent inhibitors offer the potential for more sustained target engagement. This prolonged inhibition may translate into improved therapeutic efficacy, a longer duration of action, and potentially the ability to overcome certain resistance mechanisms that arise from transient pathway inhibition or rapid enzyme reactivation. The capacity for sustained and deep inhibition is particularly relevant for signaling pathways like PI3Kα, where pathway flux can be dynamically regulated.

Molecular Interactions and Pathway Modulation (PI3K/Akt/mTOR)

By covalently inhibiting PIK3CA, TOS-358 directly intervenes in the PI3K/Akt/mTOR signaling cascade, a pathway critical for tumor cell survival and proliferation.[1] The inhibition of PI3Kα leads to a downstream reduction in the phosphorylation and activation of Akt and mTOR, ultimately resulting in the induction of apoptosis (programmed cell death) and inhibition of tumor cell growth in PIK3CA-driven cancer cells.[1] Pharmacodynamic studies have substantiated this mechanism, demonstrating a direct correlation between the occupancy of PI3Kα by TOS-358 and the suppression of key downstream signaling markers, such as phosphorylated Akt (pAkt) and phosphorylated S6 ribosomal protein (pS6).[17] Preclinical investigations suggest that achieving near-complete suppression of PI3Kα activity is crucial for eliciting sustained pathway inhibition and, consequently, inducing cancer cell death.[17] This highlights the importance of the potent and durable inhibition afforded by TOS-358's covalent binding mechanism.

Differentiation from Existing PI3Kα Inhibitors

The development of TOS-358 aims to address the limitations encountered with previous generations of PI3Kα inhibitors. It is positioned as a potentially "best-in-class" agent due to several differentiating features.[7] Firstly, its covalent mechanism of action is designed to achieve nearly 100% inhibition of PI3Kα activity, with preclinical data suggesting minimal off-target inhibition (reportedly <1%).[4] This high degree of specificity is critical because many earlier PI3K inhibitors, particularly pan-PI3K inhibitors or less selective PI3Kα inhibitors, suffered from dose-limiting toxicities, such as hyperglycemia and gastrointestinal issues. These toxicities are often attributed to the inhibition of other PI3K isoforms (e.g., PI3Kβ, PI3Kδ) involved in normal physiological processes, including glucose metabolism.[7] Preclinical studies with TOS-358 indicate that it does not cause significant hyperglycemia at therapeutically effective doses, a significant departure from the metabolic liabilities of many non-covalent PI3Kα inhibitors.[7]

Furthermore, PI3Kα signaling is often subject to pathway feedback mechanisms that can lead to the reactivation of the enzyme even in the presence of reversible inhibitors. TOS-358's covalent binding is proposed to uniquely block these feedback loops, thereby maintaining sustained pathway suppression over time, a feature not consistently achieved by non-covalent approaches.[7] This ability to achieve profound, durable, and highly specific inhibition of PI3Kα forms the basis of its potential for an improved therapeutic index, offering the prospect of enhanced anti-tumor efficacy with a more favorable safety profile.

IV. Preclinical Profile of TOS-358

In Vitro Efficacy and Potency

In vitro studies have demonstrated that TOS-358 can achieve nearly complete (approaching 100%) inhibition of PI3Kα activity. This potent inhibition leads to the induction of cell death in a variety of cancer cell lines harboring PI3Kα mutations. These cell lines span multiple tumor types, including colorectal, lung, breast, ovarian, esophageal, and head and neck cancers.[4] A critical finding from these preclinical evaluations is the observation that greater than 95% sustained inhibition of PI3Kα appears necessary to elicit significant and durable anti-tumor effects.[7] TOS-358, owing to its covalent and highly selective mechanism, is uniquely positioned to achieve this high threshold of target engagement.

In Vivo Efficacy in Xenograft Models

The anti-tumor activity of TOS-358 has been evaluated in vivo using patient-derived xenograft (PDX) and cell-derived xenograft (CDX) models of PI3Kα-mutant cancers. In these models, TOS-358 treatment has been shown to induce tumor stasis (growth inhibition) and, in some cases, tumor regression.[4] Comparative studies within these preclinical models have indicated that TOS-358 exhibits superior efficacy when compared to existing non-covalent PI3Kα inhibitors, such as alpelisib and GDC-0077.[4] The spectrum of tumor types responsive to TOS-358 in these in vivo models includes breast cancer, colorectal cancer, gastric cancer, head and neck cancer, bladder cancer, and esophageal cancer, reflecting the broad potential applicability of this agent.[7]

Pharmacodynamic Studies: Target Engagement and Pathway Inhibition

To quantify the extent and duration of PI3Kα inhibition by TOS-358, a "fit-for-purpose" pharmacodynamic (PD) assay was developed and validated. This assay allows for the direct measurement of both occupied (TOS-358-bound) and total PI3Kα protein levels in various biological samples, both in vitro and in vivo.[17] Application of this PD assay in preclinical models confirmed a direct correlation between the degree of PI3Kα target occupancy by TOS-358 and the subsequent inhibition of downstream signaling markers within the PI3K/Akt/mTOR pathway, notably phospho-Akt and phospho-S6.[17] These studies reinforced the concept that near-complete and sustained suppression of PI3Kα activity is required to effectively block downstream signaling and induce cancer cell death. The PD assay has also been employed to investigate the turnover rate of the PI3Kα protein across diverse tumor types, genetic mutations, and tissue contexts, providing valuable information for optimizing dosing schedules and understanding the dynamics of target engagement.[17]

Preclinical Safety and Toxicology

Preclinical safety evaluations have been a key focus in the development of TOS-358, particularly given the toxicity challenges faced by earlier PI3K inhibitors. In 28-day repeat-dose toxicology studies conducted in rats and dogs, TOS-358 demonstrated a good overall safety profile.[16] A pivotal finding from these preclinical safety studies is that TOS-358 does not induce significant hyperglycemia at therapeutically efficacious doses in multiple animal species, including mice, rats, and dogs.[7] This is a significant advantage, as hyperglycemia has been a common and often dose-limiting toxicity for many non-covalent PI3Kα inhibitors. The favorable metabolic safety profile of TOS-358 is attributed to its high degree of selectivity for the PI3Kα isoform, thereby avoiding the inhibition of other PI3K isoforms (such as PI3Kβ) that are implicated in glucose homeostasis and whose inhibition contributes to metabolic adverse effects.[7] This combination of robust preclinical efficacy and an improved safety window, particularly the absence of significant hyperglycemia, provides a strong rationale for the clinical advancement of TOS-358.

Table 2: Summary of Key Preclinical Findings for TOS-358

Feature	Description
In Vitro Efficacy	Near 100% PI3Kα inhibition; induction of cell death in PI3Kα mutant colorectal, lung, breast, ovarian, esophageal, H&N cancer cell lines. >95% inhibition required for significant anti-tumor effects.4
In Vivo Efficacy	Tumor stasis and regression in PI3Kα mutant PDX/CDX models (breast, colorectal, gastric, H&N, bladder, esophageal). Superior efficacy to alpelisib, GDC-0077.4
Pharmacodynamics	>90-95% target engagement correlated with inhibition of pAkt and pS6. Assay developed to measure occupied and total PI3Kα and explore turnover rates.17
Preclinical Safety	Good safety profile in 28-day rat and dog toxicology studies. No significant hyperglycemia at efficacious doses in mice, rats, and dogs, attributed to high PI3Kα specificity.7

V. Clinical Development: The TOS-358-001 Study (NCT05683418)

Study Design and Objectives (Phase 1a Dose Escalation & Phase 1b Expansion)

The ongoing clinical evaluation of TOS-358 is centered around the TOS-358-001 study, registered under NCT05683418, titled "A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors".[6] This is a multicenter, open-label trial structured in two main parts: a Phase 1a dose-escalation component and a Phase 1b dose-expansion component.

The Phase 1a portion employs a standard 3+3 dose-escalation design. Its primary objectives are to determine the safety profile of TOS-358, identify any dose-limiting toxicities (DLTs), establish the Maximum Tolerated Dose (MTD), and define the Recommended Phase 2 Dose (RP2D).[6] This phase investigates both once-daily (QD) and twice-daily (BID) oral administration schedules for TOS-358.[6]

Following the determination of the RP2D, the Phase 1b portion of the study involves expanding cohorts of patients with specific tumor types known to harbor PIK3CA mutations or amplifications. The objectives of Phase 1b are to further evaluate the safety and tolerability of TOS-358 at the RP2D and to gather preliminary evidence of its anti-tumor efficacy in these defined patient populations.[6]

Primary outcome measures for the Phase 1a part include the incidence of DLTs within the first 21 days of treatment and the overall incidence and severity of adverse events (AEs) and serious adverse events (SAEs).[6] Secondary outcome measures across both phases encompass pharmacokinetic parameters (such as Cmax​, AUC, t1/2​), pharmacodynamic assessments (including target engagement in patient samples), Objective Response Rate (ORR), Duration of Response (DOR), Disease Control Rate (DCR), and Progression-Free Survival (PFS).[8] Tumor responses are assessed every 8 weeks according to RECIST 1.1 criteria.[20]

The first patient in the TOS-358-001 study was dosed in April 2023 [10], following the clinical trial registration on January 13, 2023.[20] The estimated primary completion date for the Phase 1 portion of the study is December 2025.[2] The trial aims to enroll approximately 241 participants.[10] Initial recruitment began at sites in the United States, with plans for expansion to European sites later in 2023.[16] Known U.S. locations include City of Hope Comprehensive Cancer Center, University of Cincinnati Cancer Center, Yale Cancer Center, Vanderbilt-Ingram Cancer Center, and Dana-Farber Cancer Institute.[5] Clinical trial information also indicates study sites in Spain.[14]

Patient Population and Target Indications

The TOS-358-001 study enrolls adult patients (≥ 18 years) with histologically or cytologically confirmed diagnoses of locally advanced, recurrent, or metastatic solid tumors that are incurable and harbor known PIK3CA mutations or amplifications, as determined by a validated diagnostic laboratory test.[6] Eligible patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, a life expectancy of at least 3 months, and adequate bone marrow, liver, and kidney function.[6] A key inclusion criterion is a fasting plasma glucose level below 126 mg/dL and a hemoglobin A1c (HbA1c) level below 6.5%, effectively excluding patients with a history of diabetes.[4] Generally, prior treatment with PI3K, AKT, or mTOR inhibitors is an exclusion criterion, although an exception is made for patients with breast cancer who may have received such agents previously.[6]

The tumor types initially targeted in the Phase 1a/1b study include hormone receptor-positive (HR+)/HER2-negative breast cancer, squamous cell carcinoma of the head and neck (SCCHN), urothelial cancer, and endometrial cancer.[6] The Phase 1b expansion cohorts are planned to further investigate TOS-358 in these tumor types, as well as in colorectal cancer, gastric cancer, non-small cell lung cancer (NSCLC), and select gynecological cancers such as ovarian and cervical cancer.[10]

Phase 1a Clinical Results (as of January 2025 press release / ESMO 2024 abstract for data up to April 2024)

Preliminary results from the Phase 1a dose-escalation part of the TOS-358-001 study have been reported.

• Safety and Tolerability: The dose-escalation phase was successfully completed.[8] As of April 2024, 28 patients had received TOS-358 across six dose cohorts, ranging from 10 mg to 30 mg QD and 5 mg to 15 mg BID.[20] Encouragingly, no Grade 3 or Grade 4 toxicities were reported at doses as low as 5 mg BID.[8] Adverse events were generally low-grade, appeared to be dose-dependent, and were manageable without necessitating dose reductions.[20] The MTD for the QD dosing schedule was established at 20 mg. For the BID dosing schedule, an MTD had not been reached as of the April 2024 data cut-off.[20]
• Pharmacokinetics and Pharmacodynamics: Pharmacokinetic analysis indicated that TOS-358 exposure was dose-proportional, and drug concentrations achieved were within the desired target range.[20] Pharmacodynamic assessments demonstrated robust target engagement, with over 90-95% saturation of PI3Kα observed in patient samples across all tested dose levels.[8] A minimum effective dose (MED) had not yet been formally identified.[20]
• Preliminary Anti-Tumor Activity: Early signals of clinical activity were observed with TOS-358 monotherapy across various PIK3CA-mutant cancer subtypes and at multiple dose levels.[8] This included one report of an unconfirmed complete response.[8] Furthermore, several patients treated with TOS-358 had remained progression-free for over six months.[8] These initial findings suggest that TOS-358 exhibits pan-mutant activity.

The early clinical data from Phase 1a are promising. The achievement of high target engagement at low and well-tolerated doses, coupled with initial signs of anti-tumor activity including a complete response and durable disease control in some patients, represents a significant positive development. This profile appears to differentiate TOS-358 from many earlier PI3K inhibitors that were often hampered by a narrow therapeutic window due to toxicity. The dose-proportional pharmacokinetics further support predictable drug exposure.

Phase 1b Expansion Trial: Current Status and Future Directions

Following the encouraging results from the dose-escalation phase, the Phase 1b expansion portion of the TOS-358-001 study was initiated as of January 2025.[8] This expansion phase is focusing on further evaluating TOS-358 in specific cohorts of patients with breast cancer, endometrial cancer, urothelial cancer, and head and neck cancer, initially at doses of 5 mg and 8 mg BID.[8]

Looking ahead, Totus Medicines has planned additional Phase 1b investigations. These include a study evaluating TOS-358 in combination with fulvestrant for patients with HER2-negative breast cancer, and TOS-358 as a monotherapy for patients with bladder cancer, with an anticipated initiation in the second half of 2024.[20] The favorable safety profile observed at low, yet effective, doses of TOS-358 also supports its potential for use in combination regimens with other standard-of-care agents, such as CDK4/6 inhibitors and Selective Estrogen Receptor Degraders (SERDs), particularly in hormone-sensitive cancers like HR+ breast cancer.[8] The move into specific tumor-type expansions and the exploration of combination therapies are logical progressions in the clinical development of TOS-358. The selection of combination partners like fulvestrant, and the consideration of CDK4/6 inhibitors and SERDs, aligns with current therapeutic strategies for PIK3CA-mutated malignancies, especially HR+ breast cancer. The promising safety profile of TOS-358 is a key enabler for these combination approaches, as it may allow for enhanced efficacy without a significant increase in overlapping toxicities.

Table 3: Design of the TOS-358-001 (NCT05683418) Clinical Trial

Feature	Details
Official Title	A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors 6
ClinicalTrials.gov ID	NCT05683418 5
Phase	Phase 1/1b 8
Sponsor	Totus Medicines Inc. 20
Key Objectives (Phase 1a)	Determine MTD, RP2D, safety, and tolerability of TOS-358 (oral, QD and BID schedules) 6
Key Objectives (Phase 1b)	Further evaluate safety, tolerability, and preliminary efficacy in tumor-specific cohorts at RP2D 6
Target Population	Adults with select advanced/metastatic solid tumors (HR+/HER2- breast, SCCHN, urothelial, endometrial, colorectal, gastric, NSCLC, ovarian, esophageal) with PIK3CA mutations/amplifications 6
Intervention	TOS-358, oral, QD or BID schedules 4
Status	Recruiting 14

Table 4: Summary of Reported Phase 1a Clinical Data for TOS-358 (as of Jan 2025/ESMO 2024)

Metric	Finding
Number of Patients Treated (Apr 2024)	28 20
Dose Cohorts Evaluated (Apr 2024)	10-30 mg QD; 5-15 mg BID 20
Key Safety/Tolerability	MTD for QD: 20mg. MTD for BID: Not reached (as of Apr 2024). AEs mostly low-grade, manageable. No Grade 3/4 toxicities at 5 mg BID.8
Pharmacokinetics	Dose-proportional PK; concentrations within target range.20
Pharmacodynamics	>90-95% target engagement of PI3Kα at all dose levels.8
Preliminary Efficacy	Pan-mutant activity; 1 unconfirmed Complete Response; several patients progression-free >6 months; monotherapy activity across multiple PIK3CA-mutant cancer subtypes.8

VI. Intellectual Property Landscape

Overview of Key Patents and Applications

Totus Medicines is actively pursuing intellectual property protection for its novel compounds, including TOS-358. The company's pipeline features TOS-358 as a covalent PI3Kα inhibitor and also includes an AKT covalent inhibitor in preclinical development.[8] While some databases suggest a large number of patents associated with TOS-358 (e.g., "100 Patents (Medical) associated with TOS-358" from Synapse), specific details often require further investigation beyond publicly accessible summaries.[3]

Pitchbook data indicates that Totus Medicines holds a portfolio of 21 patent documents, comprising 4 granted patents and 17 pending applications.[26] A particularly relevant recent patent application is AU-2023240100-A1, titled "Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof." This application, with a first filing date of March 24, 2022, is currently pending and directly pertains to PI3K inhibitors, which is highly significant for TOS-358.[26] The development of specific crystalline forms and salts is a critical step in drug development, impacting manufacturability, stability, bioavailability, and ultimately, the commercial viability of a pharmaceutical product.

Other patent applications listed for Totus Medicines, such as EP-4308121-A1, US-20240228500-A1, and EP-4308121-A4, are titled "Therapeutic conjugates" and have a first filing date of March 18, 2021.[26] While these are part of Totus's broader IP portfolio, their direct relevance to TOS-358, which is a small molecule inhibitor, needs careful assessment, as "therapeutic conjugates" often refer to larger biological entities like antibody-drug conjugates.

Further strengthening its IP position, Totus Medicines entered into a licensing agreement with the Spanish National Cancer Research Centre (CNIO) by the end of 2021. This agreement granted Totus Medicines access to a family of patented PI3K inhibitors developed by CNIO's Experimental Therapeutics Programme.[27] This licensed IP likely forms a foundational component of Totus's PI3K inhibitor program, potentially providing a springboard for the development of compounds like TOS-358 or related molecules.

Detailed information regarding a World Intellectual Property Organization (WIPO) patent application, WO2023200078A1, reportedly filed by Totus Medicines and titled 'COVALENT PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF', was not accessible through the provided materials.[29] Access to the full text of this international patent application would be invaluable for a comprehensive understanding of the specific chemical space and claims surrounding TOS-358 and related covalent PI3Kα inhibitors developed by Totus Medicines.

VII. Competitive Context and Future Perspectives

Positioning Relative to Other PI3Kα Inhibitors

TOS-358 is being developed with the aspiration of achieving a "best-in-class" profile among PI3Kα inhibitors.[7] This ambition is predicated on its distinct covalent mechanism of action, which is designed to confer high specificity and lead to sustained, near-complete target inhibition (over 95%).[4] Preclinical data strongly suggest that this level of profound and durable PI3Kα suppression is essential for eliciting significant anti-tumor effects and for overcoming common pathway feedback mechanisms that can limit the efficacy of non-covalent inhibitors.[7]

A key differentiating factor for TOS-358 is its reported improved safety profile, particularly the notable absence of significant hyperglycemia at efficacious doses in preclinical models.[7] Hyperglycemia has been a prominent and often dose-limiting toxicity for many approved and investigational PI3Kα inhibitors, such as alpelisib.[4] The ability of TOS-358 to avoid this metabolic complication, attributed to its high selectivity for PI3Kα over other isoforms, could significantly widen its therapeutic window and improve patient tolerability. If these preclinical advantages translate successfully into the clinical setting, TOS-358 could address substantial unmet medical needs in PIK3CA-driven cancers, where the utility of current PI3Kα inhibitors is often constrained by their toxicity profiles and modest efficacy.

Potential for Combination Therapies

The favorable safety profile demonstrated by TOS-358 at low, yet pharmacodynamically active, doses makes it an attractive candidate for combination therapies.[8] Combination strategies are a cornerstone of modern oncology treatment, aiming to enhance anti-tumor activity, delay or overcome resistance, and improve overall patient outcomes. Totus Medicines is actively exploring such strategies for TOS-358. A Phase 1b study is planned to evaluate TOS-358 in combination with fulvestrant, a SERD, for patients with HER2-negative breast cancer.[20] Furthermore, the company is contemplating future combinations with other standard-of-care agents, including CDK4/6 inhibitors, which are widely used in HR+ breast cancer.[8] The potential to combine TOS-358 effectively with these agents, without exacerbating toxicity, could significantly expand its clinical utility.

Unmet Needs and Future Development Trajectory

Mutations in the PIK3CA gene are among the most common oncogenic alterations across a wide spectrum of human cancers, yet the clinical impact of existing PI3Kα inhibitors has been somewhat circumscribed by issues of efficacy and toxicity.[4] TOS-358, with its differentiated profile, aims to provide a more effective and tolerable therapeutic option for patients with these malignancies. Totus Medicines envisions a broad development path for TOS-358, targeting multiple PIK3CA-mutant solid tumors, including breast, colorectal, lung, bladder, endometrial, urothelial, head and neck, ovarian, and esophageal cancers.[4]

Beyond TOS-358, Totus Medicines is leveraging its Accel™ drug discovery platform to build a pipeline of novel therapeutics. The company has a strategic drug discovery partnership with Eli Lilly and Company, covering multiple therapeutic areas, which serves as external validation for its platform technology.[9] Moreover, Totus Medicines has expressed ambitions to extend the application of its discovery engine beyond oncology into other complex disease areas, such as heart disease and neurodegeneration.[4] This broad vision suggests a long-term strategy focused on leveraging their technological capabilities to address diverse unmet medical needs.

Regulatory Status

TOS-358 is currently in the Phase 1/1b stage of clinical development.[8] As of the information available, no specific regulatory designations, such as Fast Track or Orphan Drug designation from the FDA or EMA, have been publicly announced for TOS-358.[33] Such designations are typically sought and granted based on emerging clinical data that demonstrate the potential to address serious conditions or unmet medical needs. The future regulatory trajectory of TOS-358 will be contingent upon the outcomes of ongoing and planned clinical trials.

VIII. Expert Conclusion

TOS-358 has emerged as a promising investigational agent in the challenging field of PI3Kα-targeted cancer therapy. Its core strength lies in its covalent mechanism of action, which preclinical and early clinical data suggest enables highly specific, potent, and durable inhibition of both wild-type and mutant PI3Kα. This profile appears to translate into superior preclinical efficacy compared to non-covalent inhibitors and, critically, a more favorable safety window, most notably characterized by the absence of significant hyperglycemia—a common dose-limiting toxicity for previous agents in this class. The rapid discovery and progression of TOS-358 to clinical trials, attributed to Totus Medicines' Accel™ platform, further underscores the potential innovation in their drug development approach.

Initial Phase 1a clinical results are encouraging, demonstrating high target engagement (>90-95%) at low, well-tolerated oral doses, along with early signals of anti-tumor activity, including an unconfirmed complete response and durable progression-free survival in some patients with diverse PIK3CA-mutant solid tumors. The dose-proportional pharmacokinetics observed are also favorable for predictable dosing.

Despite these promising attributes, several questions remain. The MTD for the BID dosing schedule is yet to be fully established, and long-term safety data from larger patient cohorts are needed. The true clinical efficacy of TOS-358 across various tumor types and in comparison to other PI3Kα inhibitors, particularly newer covalent or mutant-specific agents that may also be in development, will only be clarified through ongoing and future clinical trials. The success of planned combination strategies, such as with fulvestrant or CDK4/6 inhibitors, will also be pivotal in defining its ultimate role in cancer treatment.

The intellectual property landscape, particularly the patent application for crystalline forms and salts (AU-2023240100-A1), will be important for future commercialization. Accessing the full details of international patent applications like WO2023200078A1 would provide a clearer picture of the proprietary claims surrounding TOS-358.

Opportunities for TOS-358 are significant, given the high prevalence of PIK3CA mutations and the unmet need for more effective and tolerable treatments. Its potential for broad applicability across multiple cancer types and its suitability for combination therapies represent major avenues for development. Threats include the competitive landscape of PI3K pathway inhibitors and the inherent risks associated with clinical drug development.

In summary, TOS-358 represents a scientifically well-rationalized approach to PI3Kα inhibition. If the promising preclinical and early clinical profile is substantiated in larger, later-phase trials, TOS-358 has the potential to become a valuable therapeutic option for patients with PIK3CA-driven cancers, offering a much-needed improvement in both efficacy and tolerability over existing treatments. Continued monitoring of its clinical development, particularly data from the Phase 1b expansion cohorts and combination studies, will be crucial in fully assessing its therapeutic impact.

Note: The CAS Number, Molecular Formula, and a detailed Chemical Structure (e.g., image, SMILES, InChI) for TOS-358 were not available in the provided research material.

Works cited

1. Definition of PI3K-alpha inhibitor TOS-358 - NCI Drug Dictionary, accessed May 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-alpha-inhibitor-tos-358
2. TOS-358 Drug Profile - Ozmosi, accessed May 23, 2025, https://pryzm.ozmosi.com/product/tos-358
3. TOS-358 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 23, 2025, https://synapse.patsnap.com/drug/f8d2c0db31f540be9a82ed19ae9492e3
4. Pipeline - Totus Medicines, accessed May 23, 2025, https://www.totusmedicines.com/pipeline
5. Clinical Trials Search at Vanderbilt-Ingram Cancer Center, accessed May 23, 2025, https://vicc.org/clinical-trials/search?f%5B0%5D=investigator%3ABerlin%2C%20Jordan
6. A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults ..., accessed May 23, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2023-01194
7. Totus Medicines Announces Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting - PR Newswire, accessed May 23, 2025, https://www.prnewswire.com/news-releases/totus-medicines-announces-presentations-at-the-upcoming-american-association-for-cancer-research-aacr-annual-meeting-301792961.html
8. Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358, a Covalent PI3Ka Selective Therapy for the Treatment of Select Solid Tumors and Appoints Zelanna Goldberg as Chief Medical Officer - BioSpace, accessed May 23, 2025, https://www.biospace.com/press-releases/totus-medicines-announces-successful-completion-of-a-phase-1-dose-escalation-study-and-initiation-of-an-expansion-trial-evaluating-tos-358-a-covalent-pi3ka-selective-therapy-for-the-treatment-of-select-solid-tumors-and-appoints-zelanna-goldberg-as-chief-medical-officer
9. Totus Medicines Announces Successful Completion of a Phase - GlobeNewswire, accessed May 23, 2025, https://www.globenewswire.com/news-release/2025/01/10/3007658/0/en/Totus-Medicines-Announces-Successful-Completion-of-a-Phase-1-Dose-Escalation-Study-and-Initiation-of-an-Expansion-Trial-Evaluating-TOS-358-a-Covalent-PI3Ka-Selective-Therapy-for-th.html
10. Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors - BioSpace, accessed May 23, 2025, https://www.biospace.com/totus-medicines-announces-first-patient-dosed-in-phase-1-trial-of-tos-358-for-the-treatment-of-select-solid-tumors
11. www.cancer.gov, accessed May 23, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pi3k-alpha-inhibitor-tos-358#:~:text=Upon%20oral%20administration%2C%20PI3K%2Dalpha,in%20PIK3CA%2Dexpressing%20tumor%20cells.
12. Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene - PR Newswire, accessed May 23, 2025, https://www.prnewswire.com/news-releases/totus-medicines-emerges-from-stealth-with-revolutionary-drug-program-targeting-pi3k-alpha-oncogene-301441008.html
13. Developing a Pharmacodynamics Assay for TOS-358 with LuminexPLORE Lab - YouTube, accessed May 23, 2025, https://www.youtube.com/watch?v=U2oaq04iOBU
14. TOS-358 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed May 23, 2025, https://synapse-patsnap-com.libproxy1.nus.edu.sg/drug/f8d2c0db31f540be9a82ed19ae9492e3
15. Totus Medicines Announces Successful Phase 1 Tos-358 Trial & Appoints New CMO, accessed May 23, 2025, https://www.clinicaltrialvanguard.com/news/totus-medicines-announces-successful-phase-1-tos-358-trial-appoints-new-cmo/
16. Abstract CT249: A study to evaluate the safety and tolerability of the ..., accessed May 23, 2025, https://aacrjournals.org/cancerres/article/83/8_Supplement/CT249/725547/Abstract-CT249-A-study-to-evaluate-the-safety-and
17. Development and validation of a pharmacodynamic (PD) assay for ..., accessed May 23, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/2249/722550/Abstract-2249-Development-and-validation-of-a
18. Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor ..., accessed May 23, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/4946/724920/Abstract-4946-TOS-358-a-first-in-class-covalent
19. Inhibition of wild-type PI3Kα signaling is required for durable efficacy ..., accessed May 23, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/4945/724872/Abstract-4945-Inhibition-of-wild-type-PI3K
20. ESMO24 Oncology Report – OBiS, accessed May 23, 2025, https://www.obis.com/reports/esmo24-oncology-report/
21. 625P - Initial results from the phase I, first-in-human study of the covalent, PI3Kα inhibitor TOS-358 in patients with solid tumors, expressing PI3Kα mutations or amplifications - ESMO Congress 2024 | OncologyPRO, accessed May 23, 2025, https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/initial-results-from-the-phase-i-first-in-human-study-of-the-covalent-pi3ka-inhibitor-tos-358-in-patients-with-solid-tumors-expressing-pi3ka-mut
22. Category - Totus Medicines, accessed May 23, 2025, https://www.totusmedicines.com/category
23. A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors | Dana-Farber Cancer Institute, accessed May 23, 2025, https://www.dana-farber.org/clinical-trials/23-618
24. Clinical Trials - Totus Medicines, accessed May 23, 2025, https://www.totusmedicines.com/clinical-trials
25. Totus Medicines, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed May 23, 2025, https://synapse.patsnap.com/organization/d4b994f4db9e2b8326c2c17c5ef1add8
26. Totus Medicines 2025 Company Profile: Valuation, Funding & Investors | PitchBook, accessed May 23, 2025, https://pitchbook.com/profiles/company/458228-89
27. CNIO and Totus Medicines form partnership to develop new generation of anti-cancer molecules, accessed May 23, 2025, https://www.cnio.es/en/news/cnio-and-totus-medicines-form-partnership-to-develop-new-generation-of-anti-cancer-molecules/
28. ANNUAL REPORT 2021 - CNIO, accessed May 23, 2025, https://www.cnio.es/downloads/annual-report/2021/cnio-annual-report-2021.pdf
29. patents.google.com, accessed May 23, 2025, https://patents.google.com/patent/WO2023200078A1/en
30. accessed January 1, 1970, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023200078
31. accessed January 1, 1970, https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023200078&_cid=P20-M0Y22W-77791-1
32. Totus Medicines, accessed May 23, 2025, https://www.totusmedicines.com/
33. Browse Trials - BreastCancerTrials.org, accessed May 23, 2025, https://www.breastcancertrials.org/bct_nation/browse_trials.seam?zip=94107&treatment=true&nonTreatment=true&advancedStage=true&radiusMiles=-1
34. FDA Oncology Actions: March 2025 Approvals and Designations, accessed May 23, 2025, https://www.targetedonc.com/view/fda-oncology-actions-march-2025-approvals-and-designations
35. Most FDA and EMA Oncology Drug Approvals in Q1 2025 Were New Indications for Biologics and Biosimilars - Aptitude Health, accessed May 23, 2025, https://www.aptitudehealth.com/oncology-news/most-fda-and-ema-oncology-drug-approvals-in-q1-2025-were-new-indications-for-biologics-and-biosimilars/
36. POS AM - SEC.gov, accessed May 23, 2025, https://www.sec.gov/Archives/edgar/data/1637715/000119312525058954/d184865dposam.htm